IGA success
Fig. 1. · Panel IGA_success
Panel IGA_success 是同一 Fig. 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Andreas Wollenberg, Jonathan I Silverberg, Franz J Legat, Marie Tauber, Vivian T Laquer, April W Armstrong, Andrew E Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty
Acta Derm Venereol 106 0085
Nemolizumab with background topical therapy (corticosteroids±calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&2) in adolescents and adults with moderate-to-severe atopic dermatitis through week (W)16. Efficacy and safety of nemolizumab, combined with background topical therapy, were evaluated for an additional 32 weeks (W16-W48) with a focus on maintained skin responses in clinical responders (patients achieving Investigator's Global Assessment [IGA] score of 0/1 [clear/almost clear] or ≥75% improvement in Eczema Area and Severity Index [EASI-75] at W16). At W16, clinical responders (N=507) to nemolizumab every 4 weeks (Q4W) were rerandomized (1 : 1 : 1) to receive nemolizumab 30 mg-Q4W/-Q8W/placebo (nemolizumab-withdrawal) subcutaneously with background topical therapy. At W48, 61.5% (strata-adjusted difference versus nemolizumab-withdrawal group [Δ], 11.8% [95% CI 1.3-22.3]) and 76.3% (Δ, 12.4% [95% CI 2.7- 22.0]) of patients in nemolizumab-Q4W; 60.4% (Δ, 10.7% [95% CI 0.3-21.0]) and 75.7% (Δ, 11.8% [95% CI 2.1-21.5]) in nemolizumab-Q8W; and 49.7% and 63.9% in nemolizumab-withdrawal group maintained response rate for IGA success and EASI-75, respectively. The percentage of patients who experienced ≥1 adverse events were similar across the groups (range: 53.5%-58.3%). Up to W48, skin responses were maintained without notable differences in the safety profile of both nemolizumab dosing regimens.
1 个 Figure · 2 个 KM 面板
Response rate for IGA success a and EASI-75 b up to 48 weeks (intent-to-treat population, non-responder imputation analysis). The initial baseline value was the last valid value prior to the first injection of study treatment of the initial period. The initial period was from day 1/baseline to W16. For non-responder imputation, patients with data collected after use of rescue therapy or with missing data at a visit were considered non-responders. a Investigator’s Global Assessment success was defined as 0/1 [clear/almost clear] and a ≥2-point reduction on the IGA scale from the initial baseline. b EASI-75 was defined as ≥75% improvement in EASI from the initial baseline. CI: confidence interval; EASI: Eczema Area and Severity Index; IGA: Investigator’s Global Assessment; Q4/8W: every 4/8 weeks.
Fig. 1. · Panel IGA_success
Panel IGA_success 是同一 Fig. 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1. · Panel EASI-75
Panel EASI-75 是同一 Fig. 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。